DE:BXT Stock Latest News
Company AnnouncementsBioNxt Extends Convertible Debentures and Issues 16.9 Million Warrants2M ago
Company AnnouncementsBioNxt Boosts Investor Relations Efforts With New Mandates and 5.15 Million Option Grants8M ago
Company AnnouncementsBioNxt Wipes Out $2.7 Million Debt Through Share Issuance8M ago
Company AnnouncementsBioNxt Moves to Retire $2.7 Million in Debenture Debt via Share Issuance9M ago- Company AnnouncementsBioNxt’s Sublingual Cladribine Film Delivers 40% Higher Exposure in Preclinical MS Study9M ago
Company AnnouncementsBioNxt’s Cladribine Film Shows Superior Bioavailability in Preclinical MS Study9M agoCompany AnnouncementsBioNxt Advances Thin-Film Drug Platform With First Patent for Sublingual Cladribine9M ago
Company AnnouncementsBioNxt Signs Agreement for Sublingual Chemotherapy and Immunosuppressant Innovation10M ago
Company AnnouncementsBioNxt Secures Eurasian Patent for Sublingual Cladribine Platform10M ago- Company AnnouncementsBioNxt Unveils Innovative Oral Film to Transform MS Treatment10M ago
Company AnnouncementsBioNxt Secures Eurasian Patent Readiness for Sublingual Drug Delivery12M ago
Company AnnouncementsBioNxt Secures European Patent for Innovative MS Treatment12M ago
Company AnnouncementsBioNxt Solutions Completes Debt Settlement to Strengthen Financial Position12M ago
TipRanks NewswireBioNxt Enters the Final Stretch Before Human Trials for Next-Generation MS Drug1y ago
Company AnnouncementsBioNxt Advances Cladribine Sublingual Film for MS Treatment1y ago- Company AnnouncementsBioNxt Solutions Adapts AGM Voting Amid Postal Strike and Launches Marketing Campaign1y ago
Company AnnouncementsBioNxt Advances Semaglutide Oral Film with Successful Trials1y agoCompany AnnouncementsBioNxt Solutions Strengthens Market Position with Strategic Advisor and Investor Relations Team1y ago
